• Something wrong with this record ?

High CXCR3 on Leukemic Cells Distinguishes IgHVmut from IgHVunmut in Chronic Lymphocytic Leukemia: Evidence from CD5high and CD5low Clones

G. Manukyan, T. Papajik, Z. Mikulkova, R. Urbanova, VS. Kraiczova, J. Savara, M. Kudelka, P. Turcsanyi, E. Kriegova

. 2020 ; 2020 (-) : 7084268. [pub] 20200620

Language English Country Egypt

Document type Journal Article

Grant support
NV16-32339A MZ0 CEP Register

Despite the shared pattern of surface antigens, neoplastic cells in chronic lymphocytic leukemia (CLL) are highly heterogeneous in CD5 expression, a marker linked to a proliferative pool of neoplastic cells. To further characterize CD5high and CD5low neoplastic cells, we assessed the chemokine receptors (CCR5, CCR7, CCR10, CXCR3, CXCR4, CXCR5) and adhesion molecules (CD54, CD62L, CD49d) on the CD5high and CD5low subpopulations, defined by CD5/CD19 coexpression, in peripheral blood of CLL patients (n = 60) subgrouped according to the IgHV mutational status (IgHVmut, n = 24; IgHVunmut, n = 36). CD5high subpopulation showed a high percentage of CXCR3 (P < 0.001), CCR10 (P = 0.001), and CD62L (P = 0.031) and high levels of CXCR5 (P = 0.005), CCR7 (P = 0.013) compared to CD5low cells expressing high CXCR4 (P < 0.001). Comparing IgHVmut and IgHVunmut patients, high levels of CXCR3 on CD5high and CD5low subpopulations were detected in the IgHVmut patients, with better discrimination in CD5low subpopulation. Levels of CXCR3 on CD5low subpopulation were associated with time to the next treatment, thus further confirming its prognostic value. Taken together, our analysis revealed higher CXCR3 expression on both CD5high and CD5low neoplastic cells in IgHVmut with a better prognosis compared to IgHVunmut patients. Contribution of CXCR3 to CLL pathophysiology and its suitability for prognostication and therapeutic exploitation deserves future investigations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020446
003      
CZ-PrNML
005      
20210830102128.0
007      
ta
008      
210728s2020 ua f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2020/7084268 $2 doi
035    __
$a (PubMed)32802894
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ua
100    1_
$a Manukyan, Gayane $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital, Olomouc, Czech Republic $u Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, Yerevan, Armenia
245    10
$a High CXCR3 on Leukemic Cells Distinguishes IgHVmut from IgHVunmut in Chronic Lymphocytic Leukemia: Evidence from CD5high and CD5low Clones / $c G. Manukyan, T. Papajik, Z. Mikulkova, R. Urbanova, VS. Kraiczova, J. Savara, M. Kudelka, P. Turcsanyi, E. Kriegova
520    9_
$a Despite the shared pattern of surface antigens, neoplastic cells in chronic lymphocytic leukemia (CLL) are highly heterogeneous in CD5 expression, a marker linked to a proliferative pool of neoplastic cells. To further characterize CD5high and CD5low neoplastic cells, we assessed the chemokine receptors (CCR5, CCR7, CCR10, CXCR3, CXCR4, CXCR5) and adhesion molecules (CD54, CD62L, CD49d) on the CD5high and CD5low subpopulations, defined by CD5/CD19 coexpression, in peripheral blood of CLL patients (n = 60) subgrouped according to the IgHV mutational status (IgHVmut, n = 24; IgHVunmut, n = 36). CD5high subpopulation showed a high percentage of CXCR3 (P < 0.001), CCR10 (P = 0.001), and CD62L (P = 0.031) and high levels of CXCR5 (P = 0.005), CCR7 (P = 0.013) compared to CD5low cells expressing high CXCR4 (P < 0.001). Comparing IgHVmut and IgHVunmut patients, high levels of CXCR3 on CD5high and CD5low subpopulations were detected in the IgHVmut patients, with better discrimination in CD5low subpopulation. Levels of CXCR3 on CD5low subpopulation were associated with time to the next treatment, thus further confirming its prognostic value. Taken together, our analysis revealed higher CXCR3 expression on both CD5high and CD5low neoplastic cells in IgHVmut with a better prognosis compared to IgHVunmut patients. Contribution of CXCR3 to CLL pathophysiology and its suitability for prognostication and therapeutic exploitation deserves future investigations.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $7 D015415
650    _2
$a antigeny CD5 $x metabolismus $7 D018956
650    _2
$a molekuly buněčné adheze $x metabolismus $7 D015815
650    _2
$a pohyb buněk $7 D002465
650    _2
$a chemotaxe $x imunologie $7 D002633
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a těžké řetězce imunoglobulinů $x genetika $7 D007143
650    _2
$a variabilní oblast imunoglobulinu $x genetika $7 D007135
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a chronická lymfatická leukemie $x diagnóza $x genetika $x metabolismus $x terapie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a ROC křivka $7 D012372
650    _2
$a receptory CXCR3 $x genetika $x metabolismus $7 D054367
650    _2
$a receptory chemokinů $x metabolismus $7 D019707
655    _2
$a časopisecké články $7 D016428
700    1_
$a Papajik, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
700    1_
$a Mikulkova, Zuzana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital, Olomouc, Czech Republic
700    1_
$a Urbanova, Renata $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
700    1_
$a Kraiczova, Veronika Smotkova $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital, Olomouc, Czech Republic
700    1_
$a Savara, Jakub $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Czech Republic
700    1_
$a Kudelka, Milos $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Czech Republic
700    1_
$a Turcsanyi, Peter $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
700    1_
$a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital, Olomouc, Czech Republic
773    0_
$w MED00186351 $t Journal of immunology research $x 2314-7156 $g Roč. 2020, č. - (2020), s. 7084268
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32802894 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102128 $b ABA008
999    __
$a ok $b bmc $g 1691090 $s 1140892
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 2020 $c - $d 7084268 $e 20200620 $i 2314-7156 $m Journal of immunology research $n J. immunol. res. $x MED00186351
GRA    __
$a NV16-32339A $p MZ0
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...